MedTrace Logo

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2025-12-08

No results posted yet for this study

Summary

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Conditions

Interventions

DRUG

Trastuzumab deruxtecan

T-DXd: administered as an IV infusion

DRUG

Durvalumab

Durvalumab: administered as an IV infusion

DRUG

Paclitaxel

Paclitaxel: administered as an IV infusion

DRUG

Pertuzumab

Pertuzumab: administered as an IV infusion

DRUG

Tucatinib

Tucatinib administered orally (tablet) twice daily

Sponsors & Collaborators

  • Daiichi Sankyo Company, Limited

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-28
Primary Completion
2025-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • France
  • Germany
  • India
  • Italy
  • Poland
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04538742 on ClinicalTrials.gov